Oncology Venture gets option to in-license European rights to IXEMPRA
Category: #headlines  By Nikita Chaurasia  Date: 2019-04-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Oncology Venture gets option to in-license European rights to IXEMPRA

Oncology Venture has reportedly gained an exclusive option to in-license the European rights to IXEMPRA® (ixabepilone) from the pharma company R-Pharm U.S., LLC. As per trusted sources, the aforesaid firm acquired global rights to IXEMPRA® from Bristol-Myers Squibb in July 2015 and the drug is permitted in the USA for the treatment of breast cancer.

Oncology Venture will assess ixabepilone along with its drug-specific DRP® companion diagnostic to obtain market approval in Europe.

According to a press release by Oncology Venture, the company has assessed the capacity of its DRP® companion diagnostic to detect which patients will most likely benefit from ixabepilone, depending on previous treatment results and information on tumor gene published by BMS in the scientific literature. The study specifies that patients profiting from Ixabepilone can be recognized through ixabepilone-specific DRP® companion diagnostic. Moreover, the company is certain that it will prevail in its quest to gain EMA approval in order to market ixabepilone across Europe to treat individuals with metastatic breast cancer.

As per the agreement, IXEMPRA® (ixabepilone) will undergo clinical trials in Europe with metastatic breast cancer patients, where the drug will be evaluated by Oncology Venture together with its DRP® companion diagnostic. If the trials unveil convincing results, Oncology Venture will have the option to in-license the commercial rights for IXEMPRA® in the European market. The extended pipeline is not anticipated to surge Oncology Venture’s cost base as the clinical development of ixabepilone will be funded via a special purpose vehicle/joint venture to be open to interested investors while the program will be controlled by Oncology Venture. 

For the record, ixabepilone was initially developed by Bristol-Myers Squibb and was permitted for the treatment of metastatic breast cancer by the US FDA in 2007 but failed to receive approval from the European Medicines Agency for the drug to be marketed in Europe. Currently, the product is marketed by R-Pharm in the USA, as well as in Switzerland, Lichtenstein and some parts of South America, reported sources.

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Atkore announces acquisition of Rocky Mountain Colby Pipe Co. assets
Atkore announces acquisition of Rocky Mountain Colby Pipe Co. assets
By Nikita Chaurasia

Atkore expands product portfolio with acquisition of Cor-Tek™ by Rocky Mountain  Atkore International Group Inc., a US-based electric solutions provider recently announced acquisition of assets of Rocky Mountain Colby Pipe Co., a front-ru...

Self-driving tech firm Waymo’s cars to be rain-tested in Florida
Self-driving tech firm Waymo’s cars to be rain-tested in Florida
By Nikita Chaurasia

Waymo is about to rain test some of its autonomous vehicles in Florida. The company wants to check if the autonomous driving technology withstands the heavy rainfall of the U.S state. The test aims to check how the vehicle's sensor suite includin...

Google blocks some data on Android devices for wireless carriers
Google blocks some data on Android devices for wireless carriers
By Nikita Chaurasia

Google decided to take this step over the fear of increasing data privacy problems across the world.   This step has disappointed the carriers using the service for various decision making processes like deciding where to upgrade and extend ...